PMC:7571312 / 556-1040 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T8747","span":{"begin":138,"end":145},"obj":"Body_part"}],"attributes":[{"id":"A77659","pred":"fma_id","subj":"T8747","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"for coronavirus replication. The 3CLpro sequences for CoV-1 and CoV-2 viruses are 100% identical in the catalytic domain that carries out protein cleavage. A research effort that focused on the discovery of reversible and irreversible ketone-based inhibitors of SARS CoV-1 3CLpro employing ligand-protease structures solved by X-ray crystallography led to the identification of 3 and 4. Preclinical experiments reveal 4 (PF-00835231) as a potent inhibitor of CoV-2 3CLpro with suitabl"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T8","span":{"begin":262,"end":266},"obj":"Disease"}],"attributes":[{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"for coronavirus replication. The 3CLpro sequences for CoV-1 and CoV-2 viruses are 100% identical in the catalytic domain that carries out protein cleavage. A research effort that focused on the discovery of reversible and irreversible ketone-based inhibitors of SARS CoV-1 3CLpro employing ligand-protease structures solved by X-ray crystallography led to the identification of 3 and 4. Preclinical experiments reveal 4 (PF-00835231) as a potent inhibitor of CoV-2 3CLpro with suitabl"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T12954","span":{"begin":70,"end":77},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T9960","span":{"begin":156,"end":157},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T99506","span":{"begin":179,"end":186},"obj":"http://purl.obolibrary.org/obo/CLO_0009985"},{"id":"T95582","span":{"begin":437,"end":438},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"for coronavirus replication. The 3CLpro sequences for CoV-1 and CoV-2 viruses are 100% identical in the catalytic domain that carries out protein cleavage. A research effort that focused on the discovery of reversible and irreversible ketone-based inhibitors of SARS CoV-1 3CLpro employing ligand-protease structures solved by X-ray crystallography led to the identification of 3 and 4. Preclinical experiments reveal 4 (PF-00835231) as a potent inhibitor of CoV-2 3CLpro with suitabl"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T3","span":{"begin":138,"end":145},"obj":"Chemical"},{"id":"T4","span":{"begin":235,"end":241},"obj":"Chemical"},{"id":"T5","span":{"begin":248,"end":258},"obj":"Chemical"},{"id":"T6","span":{"begin":290,"end":296},"obj":"Chemical"},{"id":"T7","span":{"begin":421,"end":423},"obj":"Chemical"},{"id":"T9","span":{"begin":446,"end":455},"obj":"Chemical"}],"attributes":[{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_17087"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_52214"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_74795"},{"id":"A8","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_90284"},{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"for coronavirus replication. The 3CLpro sequences for CoV-1 and CoV-2 viruses are 100% identical in the catalytic domain that carries out protein cleavage. A research effort that focused on the discovery of reversible and irreversible ketone-based inhibitors of SARS CoV-1 3CLpro employing ligand-protease structures solved by X-ray crystallography led to the identification of 3 and 4. Preclinical experiments reveal 4 (PF-00835231) as a potent inhibitor of CoV-2 3CLpro with suitabl"}

{"project":"LitCovid-sentences","denotations":[{"id":"T5","span":{"begin":29,"end":155},"obj":"Sentence"},{"id":"T6","span":{"begin":156,"end":386},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"for coronavirus replication. The 3CLpro sequences for CoV-1 and CoV-2 viruses are 100% identical in the catalytic domain that carries out protein cleavage. A research effort that focused on the discovery of reversible and irreversible ketone-based inhibitors of SARS CoV-1 3CLpro employing ligand-protease structures solved by X-ray crystallography led to the identification of 3 and 4. Preclinical experiments reveal 4 (PF-00835231) as a potent inhibitor of CoV-2 3CLpro with suitabl"}

{"project":"LitCovid-PubTator","denotations":[{"id":"22","span":{"begin":4,"end":15},"obj":"Species"},{"id":"23","span":{"begin":54,"end":57},"obj":"Species"},{"id":"24","span":{"begin":64,"end":69},"obj":"Species"},{"id":"25","span":{"begin":262,"end":270},"obj":"Species"},{"id":"26","span":{"begin":459,"end":464},"obj":"Species"},{"id":"27","span":{"begin":235,"end":241},"obj":"Chemical"}],"attributes":[{"id":"A22","pred":"tao:has_database_id","subj":"22","obj":"Tax:11118"},{"id":"A23","pred":"tao:has_database_id","subj":"23","obj":"Tax:11118"},{"id":"A24","pred":"tao:has_database_id","subj":"24","obj":"Tax:2697049"},{"id":"A25","pred":"tao:has_database_id","subj":"25","obj":"Tax:694009"},{"id":"A26","pred":"tao:has_database_id","subj":"26","obj":"Tax:2697049"},{"id":"A27","pred":"tao:has_database_id","subj":"27","obj":"MESH:D007659"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"for coronavirus replication. The 3CLpro sequences for CoV-1 and CoV-2 viruses are 100% identical in the catalytic domain that carries out protein cleavage. A research effort that focused on the discovery of reversible and irreversible ketone-based inhibitors of SARS CoV-1 3CLpro employing ligand-protease structures solved by X-ray crystallography led to the identification of 3 and 4. Preclinical experiments reveal 4 (PF-00835231) as a potent inhibitor of CoV-2 3CLpro with suitabl"}